lung
diseas
caus
enorm
socioeconom
burden
four
among
ten
import
caus
death
worldwid
pneumonia
highest
death
toll
infecti
diseas
lung
cancer
kill
peopl
malign
prolif
disord
chronic
obstruct
pulmonari
diseas
copd
rank
third
mortal
among
chronic
noncommunic
diseas
tuberculosi
still
one
import
chronic
infecti
diseas
despit
effort
exampl
world
health
organ
clinic
experiment
research
diseas
still
highli
preval
harm
part
due
specifi
c
organ
tissu
homeostasi
architectur
immun
lung
recent
sever
consortia
form
aim
bring
togeth
clinic
molecular
data
big
cohort
patient
lung
diseas
novel
experiment
setup
biostatist
bioinformat
mathemat
model
system
medicin
concept
help
match
differ
diseas
modal
adequ
therapeut
possibl
prevent
strategi
individu
patient
sens
precis
medicin
among
ten
common
caus
death
worldwid
four
pulmonari
diseas
kill
million
peopl
per
year
fig
addit
pneumonia
copd
tuberculosi
lung
cancer
also
among
ten
common
caus
disabilityadjust
life
year
dali
lost
worldwid
pneumonia
alon
singl
import
caus
dali
lost
import
hivaid
ischem
heart
diseas
cerebrovascular
diseas
diarrhea
total
cost
lung
diseas
european
union
amount
billion
annual
addit
abovement
diseas
asthma
alon
caus
cost
billion
consist
billion
direct
medic
cost
billion
lost
product
work
absenc
earli
retir
etc
billion
monet
valu
dali
lung
cancer
caus
greatest
socioeconom
loss
disabl
prematur
mortal
late
diagnosi
limit
treatment
option
treatment
cost
concentr
within
year
diagnosi
therefor
total
annual
cost
per
case
calcul
lung
cancer
lung
airway
provid
mani
uniqu
featur
term
anatomi
physiolog
immunolog
pave
way
manifold
patholog
present
challeng
pulmonari
clinician
research
lung
bodi
largest
organ
contain
four
liter
air
half
liter
tissu
amount
blood
therefor
organ
tissu
organ
sophist
delic
way
main
function
lung
exchang
two
gase
co
air
breath
bloodstream
three
main
process
involv
ventil
air
along
bronchial
tree
passiv
diffus
gase
perfus
blood
alveolar
capillari
process
tightli
regul
everi
part
lung
equal
ventil
perfus
everi
day
l
aircontain
pollut
allergen
pathogen
etci
ventil
gener
dichotom
divid
airway
lung
surfac
condens
mainli
million
alveoli
capillari
surfac
size
diffus
oxygen
critic
depend
short
diffus
distanc
airblood
barrier
healthi
lung
mean
thick
tissu
barrier
consist
thin
part
alveolar
epitheli
type
cell
capillari
endotheli
cell
share
one
singl
layer
basement
membran
delic
architectur
possibl
due
surfact
layer
line
alveolar
surfac
reduc
surfac
tension
releas
alveolar
epitheli
type
ii
cell
communityacquir
pneumonia
high
incid
diseas
result
hospit
admiss
per
year
industri
countri
myocardi
infarct
highest
mortal
rate
worldwid
infecti
diseas
lethal
rang
outpati
set
highrisk
patient
unicef
unit
nation
children
fund
data
suggest
pneumonia
kill
children
age
malaria
aid
measl
togeth
notori
problem
emerg
new
pathogen
may
combin
high
mortal
easi
transmiss
eg
sar
mer
coronavirus
certain
pandem
infl
uenza
strain
sever
pneumonia
lead
sepsi
septic
shock
requir
intens
care
treatment
artifi
cial
organ
support
caus
extrem
high
cost
recent
observ
pneumonia
patient
face
increas
death
risk
sever
month
acut
infect
asthma
classic
defi
ned
infl
ammatori
chronic
airway
diseas
character
revers
airway
obstruct
airway
hyperrespons
diseas
affect
million
peopl
worldwid
preval
increas
last
decad
asthmat
consid
sever
case
typic
infl
ammat
asthma
describ
allerg
eosinophil
ige
depend
driven
therefor
therapi
besid
bronchodil
target
mainli
eosinophil
infl
ammat
either
unspecifi
c
topic
system
glucocorticoid
antileukotrien
drug
biolog
therapi
specifi
calli
address
ige
probabl
futur
other
howev
suffi
cient
control
asthma
symptom
imposs
mani
patient
part
due
asthma
patient
show
persist
eosinophil
infl
ammat
serious
challeng
classic
pathophysiolog
concept
systemsbas
approach
help
stratifi
patient
phenotyp
respect
avail
therapi
identifi
new
target
treatment
patient
unrespons
exist
drug
chronic
obstruct
pulmonari
diseas
copd
third
common
noncommunic
diseas
high
preval
worldwid
caus
signifi
cant
disabl
mortal
healthcar
cost
eg
lifelong
medic
lung
transplant
mechan
ventil
common
caus
develop
copd
longterm
exposur
primari
secondari
tobacco
smoke
combust
biomass
eg
openfi
cook
develop
countri
genet
predisposit
increas
evid
indic
copd
rather
syndrom
solitari
diseas
pathophysiolog
hallmark
chronic
cortisoneinsensit
infl
ammat
caus
mucu
hypersecret
fi
xed
bronchoconstrict
remodel
well
irrevers
tissu
destruct
term
bronchiectasi
emphysema
result
respiratori
ventilatori
failur
aggrav
aspect
viciou
circl
impair
innat
immun
chronic
bacteri
colon
recurr
viral
bacteri
infect
call
exacerb
often
result
hospit
besid
substanc
avoid
exercis
train
copd
symptom
typic
treat
longact
airway
dilat
lifelong
basi
underli
pathophysiolog
chronic
airway
infl
ammat
target
either
topic
system
glucocorticoid
phosphodiesteras
inhibitor
howev
treatment
hamper
side
effect
low
effect
increas
number
patient
sever
ventilatori
insuffi
cienci
receiv
lifelong
mechan
ventil
expens
requir
special
infrastructur
hand
chanc
copd
patient
receiv
lung
transplant
decreas
due
high
risk
eg
cardiovascular
metabol
comorbid
pulmonari
hypertens
diseas
lung
vasculatur
hallmark
deregul
prolifer
differ
vascular
cell
type
progress
obliter
vessel
often
result
increas
pulmonari
vascular
resist
increas
right
heart
afterload
cor
pulmonal
pulmonari
hypertens
caus
combin
genet
environment
factor
occur
varieti
clinic
situat
heterogen
phenotyp
sever
histolog
pattern
abnorm
describ
despit
signifi
cant
progress
made
understand
pathogenesi
develop
new
method
delay
progress
diseas
still
cure
lung
cancer
display
highest
neoplasiarel
mortal
man
last
year
mortal
also
increas
women
cure
rate
prognosi
gener
poor
due
late
diagnosi
therefor
major
focu
lie
screen
earli
diagnosi
anoth
import
challeng
correct
molecular
diagnosi
target
therapi
lung
cancer
subdivid
socal
small
cell
lung
cancer
sclc
neuroendocrin
origin
nonsmal
cell
lung
cancer
nsclc
eg
squamou
cell
cancer
adenocarcinoma
recent
certain
mutat
found
predict
sensit
new
target
therapi
therefor
cancer
might
fi
rst
entiti
lung
diseas
match
concept
precis
medicin
lung
cancer
mainli
caus
exposur
primari
secondari
tobacco
smoke
biomass
combust
natur
occur
radon
basic
aim
system
medicin
model
human
pathophysiolog
diseas
advanc
understand
improv
clinic
diagnosi
treatment
therefor
logic
straightforward
strategi
establish
big
wellcharacter
patient
cohort
collect
mani
clinic
molecular
data
possibleand
suitablea
solid
base
model
process
howev
certain
process
featur
observ
test
neither
healthi
volunt
patient
includ
earli
origin
diseas
eg
environment
infl
uenc
asthma
predisposit
may
epigenet
transfer
mother
child
initi
pathophysiolog
event
alveolu
develop
infl
uenza
virusinduc
pneumonia
mani
part
problem
resolv
use
cell
cultur
tissu
cultur
model
howev
aspect
address
live
organ
past
academ
experiment
research
well
drug
candid
studi
subsequ
human
trial
mice
use
model
human
diseas
practic
conveni
easi
handl
low
cost
possibl
gener
transgen
gene
knockout
anim
avail
molecular
immunolog
tool
howev
certain
caveat
kept
mind
firstli
lung
diseas
eg
asthma
uniqu
human
occur
natur
mice
secondli
anatomi
patho
physiolog
may
differ
signifi
cantli
mice
human
besid
obviou
size
differenceth
human
lung
volum
l
murin
lung
volum
mlthere
also
signifi
cant
anatom
physiolog
differ
instanc
human
airway
gener
murin
human
airway
divis
dichotom
murin
airway
divis
monopod
mice
respiratori
bronchioli
cellular
composit
vascular
lung
differ
speci
moreov
mice
strain
differ
likelihood
react
stressor
certain
pathophysiolog
event
addit
increas
evid
immun
system
mice
men
differ
signifi
cantli
trauma
burn
endotoxemia
seok
cowork
compar
gene
respons
pattern
human
subject
correspond
mous
model
found
stressor
result
highli
similar
pattern
human
wherea
respons
correspond
mous
model
show
poor
correl
human
condit
also
among
accordingli
sever
exampl
relianc
anim
model
misguid
pathophysiolog
understand
led
unsuccess
clinic
trial
even
result
disastr
outcom
clinic
studi
may
part
due
differ
molecular
repertoir
immun
cell
mice
human
exampl
inher
versatil
macrophag
harbor
potenti
plethora
differ
activ
subtyp
inappropri
polar
detriment
host
macrophag
potenti
inapt
immun
respons
thu
aggrav
patholog
condit
rodent
alveolar
macrophag
found
play
import
role
develop
airway
hyperrespons
allerg
anim
mice
solid
marker
macrophag
polar
establish
exemplifi
ed
welldescrib
induct
argi
macrophag
correspond
function
marker
human
system
yet
found
notabl
differ
human
murin
macrophag
activ
pattern
transcript
level
accordingli
compar
studi
polar
mous
man
show
limit
interspeci
consist
transglutaminas
found
function
marker
share
frequent
caus
communityacquir
pneumonia
pneumococc
infect
smith
cowork
establish
mathemat
model
predict
outcom
pneumococc
pneumonia
two
possibl
state
bacteri
clearanc
sustain
bacteri
growth
model
base
data
pulmonari
bacteri
replic
mous
model
pneumococc
pneumonia
use
ordinari
differenti
equat
ode
describ
three
line
barrier
defens
first
initi
alveolar
macrophag
respons
mount
fast
weak
defens
describ
one
equat
bacteri
popul
second
earli
recruit
neutrophil
consist
cytokin
releas
differ
popul
alveolar
macrophag
epitheli
cell
infl
ux
neutrophil
neutrophil
apoptosi
debri
remov
alveolar
macrophag
third
subsequ
recruit
monocytederiv
macrophag
includ
contribut
bacteri
kill
model
provid
interest
insight
suffi
cient
accuraci
certain
question
although
moder
complex
base
limit
experiment
data
data
previous
publish
mous
studi
includ
anoth
effort
model
pneumococc
pneumonia
bacteri
number
lung
blood
also
neutrophil
level
infect
experi
four
differ
suscept
mous
strain
use
calibr
ode
model
consist
four
equat
describ
time
evolut
number
pathogen
lung
blood
damag
lung
epitheli
cell
total
activ
phagocyt
model
valid
publish
data
set
predict
consist
experiment
observ
howev
studi
far
model
pneumonia
dynam
patient
therefor
new
consortium
medic
system
biolog
pulmonari
barrier
failur
commun
acquir
pneumonia
e
med
capsi
aim
multiscal
model
pulmonari
barrier
failur
bacteri
pneumonia
base
comprehens
physiolog
proteom
transcriptom
data
set
clinic
cohort
complex
mous
model
human
cell
cultur
model
fig
includ
three
cohort
wellphenotyp
pneumonia
patient
capnetz
studi
clinic
biochem
genet
data
patient
uncompl
sever
pneumonia
pneumogen
sepsi
sever
visit
data
genotyp
express
profi
ling
proteom
newli
recruit
deepphenotyp
cohort
patient
undergo
eg
bronchoscopi
microbiom
exosom
analysi
sever
mathemat
model
develop
studi
understand
host
immun
respons
mechan
pulmonari
mycobacterium
tuberculosi
mtb
infect
marino
kirschner
use
two
compart
model
investig
human
immun
respons
mtb
lung
perform
bifurc
analysi
model
author
identifi
ed
key
process
cellular
activ
prime
occur
lung
nearest
drain
lymph
node
potenti
determin
differ
outcom
mtb
infect
identifi
control
mechan
granuloma
format
mtb
infect
lung
segoviajuarez
et
al
built
complex
agentbas
model
account
interact
mtb
immun
effector
chemokin
cytokin
immun
cell
like
macrophag
cell
help
model
author
identifi
ed
sever
issu
crucial
granuloma
format
cours
mtb
infect
includ
effi
cienci
chemokin
diffus
prevent
macrophag
overcrowd
within
granuloma
arriv
time
locat
number
cell
within
granuloma
well
overal
host
abil
activ
macrophag
investig
contribut
cell
control
mtb
infect
sud
et
al
built
ode
model
immun
respons
mtb
lung
use
model
author
examin
import
cell
control
infect
determin
put
minimum
cell
level
provid
effect
protect
follow
vaccin
model
differenti
equat
also
develop
investig
differ
role
play
altern
activ
macrophag
aam
versu
classic
activ
macrophag
cam
earli
stage
mtb
infect
lung
model
describ
interact
among
cell
bacteria
cytokin
involv
activ
aam
cam
use
tool
analyz
strategi
reduc
switch
time
ie
cam
becom
domin
aam
ensur
adequ
immun
respons
pathogen
similarli
kirschner
group
built
two
ode
model
investig
function
macrophag
cam
activ
cytokin
ie
tnf
ifn
mtb
infect
one
model
use
test
abil
macrophag
kill
mtb
differ
scenario
macrophag
activ
character
time
tnf
signal
rel
infect
model
simul
unravel
prefer
host
strategi
mycobacteri
control
implement
via
direct
entri
macrophag
granuloma
site
lung
vascular
sourc
model
use
predict
contribut
multipl
tnf
activ
control
mtb
infect
within
granuloma
assumpt
macrophag
activ
key
effector
mechan
control
bacteri
growth
lung
simul
result
suggest
bacteri
number
strong
contribut
factor
granuloma
structur
tnf
tnfdepend
apoptosi
reduc
infl
ammat
cost
impair
mycobacteri
clearanc
one
fundament
challeng
control
pulmonari
mtb
infect
understand
molecular
mechan
involv
onset
latenc
andor
reactiv
mtb
initi
infect
magombedz
mulder
built
mathemat
model
simul
possibl
mtb
latenc
occurr
scenario
lung
base
profi
le
differenti
express
gene
ode
model
use
simul
observ
gene
express
chang
vitro
latenc
model
allow
illustr
possibl
latencydorm
occurr
scenario
latenc
reactiv
subsequ
studi
author
use
system
biolog
approach
comb
bioinformat
mathemat
model
identifi
potenti
drug
target
gene
mtb
latenc
program
boolean
model
datadriven
regulatori
network
relat
mycobacteri
latenc
lung
reveal
bistabl
switch
latent
activ
replic
phase
mtb
multiscal
model
lung
develop
appli
gain
better
understand
asthma
sever
aspect
model
incorpor
coupl
multipl
spatial
scale
molecul
cell
tissu
lung
underli
airway
hyperrespons
simul
complex
physiolog
respons
eg
allergen
asthma
venega
et
al
carri
studi
probe
scale
ventil
heterogen
asthmat
subject
use
positron
emiss
tomographi
imag
model
complex
interdepend
behavior
lung
author
found
ventil
uniform
within
bronchoconstrict
region
within
ventil
defect
consider
ventil
heterogen
brook
et
al
develop
axisymmetr
twolay
model
airway
wall
repres
lung
slice
intact
airway
vivo
resolv
connect
tissu
muscl
cell
properti
within
composit
muscl
layer
model
predict
differ
type
airway
remodel
asthma
lead
signifi
cantli
differ
contractil
respons
stress
environ
better
understand
airway
hyperrespons
asthmat
airway
multiscal
model
partial
ordinari
differenti
equat
develop
link
regulatori
process
occur
molecular
cellular
level
ca
crossbridg
dynam
physiolog
phenomena
occur
organ
level
lung
deform
chernyavski
et
al
develop
mathemat
model
qualit
describ
growth
dynam
airway
smooth
muscl
cell
asm
short
long
term
normal
infl
ammatori
environ
typic
observ
asthma
model
allow
possibl
asm
accumul
scenario
explor
suggest
possibl
new
target
diagnosi
prevent
asm
model
asthma
recent
new
consortia
start
appli
system
biolog
strategi
asthma
clinic
context
within
innov
medicin
initi
european
project
aim
person
manag
approach
patient
sever
asthma
unbias
biomark
predict
respiratori
diseas
outcom
consortium
ubiopr
involv
scientist
univers
research
institut
pharmaceut
industri
small
compani
plan
defi
ne
phenotyp
respect
therapeut
effi
caci
integr
omic
data
invas
noninvas
obtain
patient
materi
model
underli
patholog
anoth
project
aim
develop
valid
model
predict
diseas
progress
respons
treatment
asthma
copd
integr
expertis
physiolog
radiolog
imag
analysi
bioengin
data
harmon
secur
ethic
comput
model
system
biolog
airway
diseas
predict
outcom
patient
specifi
c
comput
model
consortium
airprom
project
fund
european
union
framework
programm
recent
german
center
lung
research
dzl
establish
system
biolog
platform
integr
patient
data
cohort
childhood
wheez
sever
asthma
adult
experiment
model
mean
multiscal
model
investig
airway
diseas
result
infl
ammat
fi
brosi
follow
particul
exposur
brown
et
al
use
agentbas
model
focus
limit
number
relev
interact
specifi
calli
among
macrophag
fi
broblast
proinfl
ammatori
antiinfl
ammatori
cytokin
collagen
deposit
tissu
damag
model
predict
three
distinct
state
infl
ammat
whose
develop
depend
primarili
degre
durat
particul
exposur
predict
consist
vivo
experiment
observ
obtain
expos
mice
lung
tissu
particul
matter
mathemat
model
compos
partial
differenti
equat
describ
interact
among
immun
cell
cytokin
relat
sarcoidosi
lung
built
hao
et
al
model
calibr
valid
use
clinic
data
cytokin
level
healthi
diseas
lung
tissu
use
explor
effect
potenti
treatment
enhanc
may
reduc
diseas
activ
decreas
size
sarcoid
granuloma
taken
togeth
construct
model
step
toward
comprehens
studi
sarcoidosi
treatment
mani
endstag
respiratori
diseas
requir
lung
transplant
last
resort
howev
overal
surviv
procedur
show
poorest
longterm
surviv
solid
organ
transplant
main
reason
develop
chronic
lung
allograft
dysfunct
clad
lung
transplant
recipi
within
year
therefor
lung
transplant
center
team
build
comput
model
estim
person
recipi
risk
develop
clad
within
year
transplant
system
biolog
clad
sysclad
analyz
clinic
environment
immunolog
data
microbiom
differ
omic
data
donor
recipi
one
question
still
unsolv
lung
cancer
circul
tumor
cell
develop
primari
site
travers
circulatori
system
mind
diffi
culti
gener
suitabl
vivo
data
elucid
question
mathemat
model
system
biolog
paradigm
seem
good
methodolog
option
line
kuhn
group
use
markov
chain
mont
carlo
model
describ
cancer
progress
identifi
quantifi
multidirect
pathway
timescal
associ
metastat
spread
primari
lung
cancer
contrast
tradit
view
cancer
metastasi
unidirect
process
start
primari
site
spread
distant
site
time
progress
author
quantifi
ed
three
type
multidirect
mechan
cancer
progress
base
larg
autopsi
data
set
selfseed
primari
tumor
reseed
primari
tumor
metastat
site
reseed
metastat
tumor
simul
model
author
show
lung
cancer
main
spreader
ie
distant
site
higher
probabl
transmit
keep
circul
tumor
cell
primari
site
adren
gland
kidney
wherea
main
spong
ie
distant
site
lower
probabl
transmit
keep
circul
tumor
cell
primari
site
region
lymph
node
liver
bone
mathemat
model
util
systemlevel
understand
whole
respiratori
system
also
detail
understand
sever
function
contribut
ga
exchang
within
lung
review
bental
tawhai
particularli
two
studi
carri
investig
effect
ventilationperfus
mismatch
hepatopulmonari
syndrom
lung
infl
ammat
respect
chakraborti
et
al
develop
differenti
equat
model
pulmonari
oxygen
uptak
consid
three
dispar
scale
name
micro
red
blood
cell
meso
capillari
alveolu
macro
lung
author
use
model
quantifi
oxygen
uptak
abnorm
patient
hepatopulmonari
syndrom
result
function
intrapulmonari
right
left
shunt
pulmonari
blood
fl
ow
well
spatial
heterogen
ventilationperfus
mismatch
lung
furthermor
quantifi
ed
pulmonari
ga
exchang
abnorm
patient
use
stratifi
two
categoriesthos
oxygen
respons
oxygen
nonrespons
intract
hypoxemia
reynold
et
al
develop
multicompart
model
ode
ga
exchang
focu
infl
ammat
acut
lung
injuri
use
model
author
explor
effect
infl
ammat
ventilationperfus
distribut
result
pulmonari
venou
partial
pressur
oxygen
level
system
infl
ammatori
stress
last
year
number
compartmentbas
pharmacokinet
pk
model
account
kinet
inhal
pharmaceut
publish
instanc
sturm
develop
stochast
model
describ
mucociliari
clearanc
cystic
fi
brosi
patient
develop
progress
cours
diseas
model
show
patient
cystic
fi
brosi
higher
risk
inhal
particl
accumul
relat
particl
overload
specifi
c
lung
compart
healthi
subject
markovetz
et
al
built
complex
model
describ
mucociliari
clearanc
absorpt
aerosol
radiolabel
particl
small
molecular
probe
human
subject
without
cystic
fi
brosi
model
captur
mucociliari
clearanc
liquid
dynam
hyperabsorpt
state
cystic
fi
brosi
airway
mitig
state
hyperton
salin
treatment
despit
clinic
scientifi
c
effort
far
lung
diseas
caus
enorm
suffer
death
toll
patient
socioeconom
cost
societi
healthcar
system
especi
fi
eld
infect
malign
chronic
noncommunic
diseas
allergi
may
part
due
complic
even
prenat
timelin
heterogen
clinic
phenotyp
hand
new
scientifi
c
insight
eg
role
microbiom
noncod
rna
new
technolog
develop
eg
new
sequenc
technolog
may
help
us
improv
clinic
perform
futur
tremend
amount
clinic
molecular
data
requir
new
way
organiz
technolog
intellectu
cooper
mani
clinic
experiment
theoret
disciplin
call
system
medicin
mani
question
remain
answer
type
amount
clinic
data
need
afford
collect
analyz
role
anim
model
human
tissu
model
complex
cell
cultur
model
even
artifi
cial
organ
chip
bring
complex
multilevel
data
togeth
mean
mathemat
comput
scienc
improv
clinic
practic
respiratori
medicin
requir
enthusiasm
hard
work
particip
physician
scientist
well
sustain
support
govern
fund
agenc
stakehold
healthcar
system
